Hans de Haard

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

Peter Ulrichts, Antonio Guglietta, Torsten Dreier et al. · Journal of Clinical Investigation · 2018 · 334 citations · Full text

Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis

Ken Coppieters, Torsten Dreier, Karen Silence et al. · Arthritis & Rheumatism · 2006 · 296 citations

Protein crystallization promotes type 2 immunity and is reversible by antibody treatment

Emma K. Persson, Kenneth Verstraete, Ines Heyndrickx et al. · Science · 2019 · 289 citations · Full text

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

Klaas Vandenbroucke, Hans de Haard, Els Beirnaert et al. · Mucosal Immunology · 2009 · 279 citations

Inflammation, Nanomedicine, Anti-inflammatory +10

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

James F. Howard, Vera Bril, Ted M. Burns et al. · Neurology · 2019 · 268 citations · Full text